BioCentury | Jun 26, 2020

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

Among a trio of companies making their NASDAQ debuts on Friday, Akouos’ first-day rise of 29% was the biggest, while Fusion gave back its early gains and PolyPid also climbed in the aftermarket. Across the...
BioCentury | Jan 25, 2020
Product Development

Radiotherapy blasts forward

High-wattage takeouts and commercial launches have revived interest in radiopharmaceuticals for cancer. The challenge for the new wave of candidates is to achieve enough differentiation to justify the logistical hurdles of manufacturing and delivering products...
BioCentury | Jul 13, 2019

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BioCentury | Apr 2, 2019
Financial News

Fusion raises $105M series B for radiopharmaceutical pipeline

Aiming to advance its pipeline of targeted α-particle radiopharmaceuticals for cancer, Fusion raised $105 million in an oversubscribed series B round led by Varian and new investor OrbiMed Advisors. Fusion Pharmaceuticals Inc. (Hamilton, Ontario) labels...
BioCentury | Dec 28, 2018
Company News

Management tracks: Schwartz steps down as Kadmon chairman

Kadmon Holdings Inc. (NYSE:KDMN) said Bart Schwartz is stepping down as chairman, citing Schwartz’s increasing responsibilities at his charitable commitments. The inflammatory and fibrotic disease company is seeking a successor. CytoDyn Inc. (OTCBB:CYDY) hired Nitya...
BioCentury | Jun 7, 2018
Emerging Company Profile

Radio fusion

Fusion Pharmaceuticals Inc. is improving the safety of radiopharmaceuticals for cancer by using a proprietary linker to label antibodies with the radioisotope actinium-225. While the newco remains tight-lipped about the linker’s design, SVP of Business...
BioCentury | May 4, 2018
Company News

Fusion to identify cancer candidates with Isogenica platform

Isogenica Ltd. (Little Chesterford, U.K.) granted Fusion Pharmaceuticals Inc. (Hamilton, Ontario) rights to Isogenica's CIS display technology which Fusion will use to identify and develop cancer therapeutics. Isogenica will receive an undisclosed upfront payment and...
BioCentury | Jan 5, 2018
Clinical News

Actinium reports Phase II data for Actimab-A in AML

Actinium Pharmaceuticals Inc. (NYSE-M:ATNM) reported preliminary data from 13 evaluable patients ages 60 and older with newly diagnosed acute myelogenous leukemia (AML) who were unable to tolerate induction therapy in the Phase II portion of...
BioCentury | Oct 6, 2017

High as a Kite

The acquisition of Kite Pharma Inc. by Gilead Sciences Inc. turned what would have been a flattish quarter into another period of outperformance, and relieved the cash constraints that could have prevented specialists from continuing...
BioCentury | Oct 6, 2017
Company News

ABX grants Endocyte exclusive, worldwide rights to PSMA-targeting ligand

ABX GmbH (Radeberg, Germany) granted Endocyte Inc. (NASDAQ:ECYT) exclusive, worldwide rights to develop and commercialize prostate-specific membrane antigen ( PSMA ; FOLH1 ; GCPII)-targeting ligand PSMA-617. ABX received $12 million up front and is eligible for...
Items per page:
1 - 10 of 60